2003
DOI: 10.1023/a:1025465726691
|View full text |Cite
|
Sign up to set email alerts
|

Untitled

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
11
0
1

Year Published

2006
2006
2015
2015

Publication Types

Select...
6

Relationship

2
4

Authors

Journals

citations
Cited by 22 publications
(14 citation statements)
references
References 17 publications
2
11
0
1
Order By: Relevance
“…The DSC spectrum of XM shows an increase in its melting point, while that of AN a decrease in its melting point. A considerable increase in the melting point of irradiated XM is a phenomenon we have observed for the first time in our investigation of radiolysis of therapeutic substances [16][17][18][19][20][21]. It is supposed that this increase is related to a considerable radiolysis of this compound (three radiolysis products detected by TLC) and a high concentration of the radicals formed (the highest from among the compounds studied in this work).…”
Section: Resultssupporting
confidence: 54%
See 3 more Smart Citations
“…The DSC spectrum of XM shows an increase in its melting point, while that of AN a decrease in its melting point. A considerable increase in the melting point of irradiated XM is a phenomenon we have observed for the first time in our investigation of radiolysis of therapeutic substances [16][17][18][19][20][21]. It is supposed that this increase is related to a considerable radiolysis of this compound (three radiolysis products detected by TLC) and a high concentration of the radicals formed (the highest from among the compounds studied in this work).…”
Section: Resultssupporting
confidence: 54%
“…Differential scanning calorimetry (DSC) has been recently often used in analysis of medicaments [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19]. For many years it has been an important tool in the study of drug polymorphism [2][3][4][5][6].…”
Section: Introductionmentioning
confidence: 99%
See 2 more Smart Citations
“…O comitê da ICH também definiu, por meio da Guidance (1987), que se o fenômeno de polimorfismo for conhecido, uma instrução geral deve constar na monografia farmacopeica da seguinte forma: "a substância exibe o fenômeno de polimorfismo". [41][42][43][44][45][46][47][48][49][50] Moneghini et al relataram através de análises de DSC e DRX que o fármaco atenolol, um anti-hipertensivo, se apresentou na forma cristalina com os agentes dispersores povidona e polivinilpirrolidona/ vinil acetato, e na forma amorfa com os dispersores crospovidona e eudragit E. Os resultados coincidem com aqueles de maiores taxas de dissolução do fármaco na fase amorfa. 47 Leitão identificou quatro formas polimórficas da terfenadina, utilizando condições de recristalização diferentes para a obtenção das formas cristalinas, sendo usados solventes e temperaturas variadas e empregando DSC e DRX para caracterização dos polimorfos.…”
Section: Polimorfismounclassified